1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Guizhou Bailing Group Pharmaceutical Co., Ltd. Class A

Guizhou Bailing Group Pharmaceutical Co., Ltd. Class A

SSZSE:002424
4.60
CNY
-0.01
(-0.22%)
-0.08EPS
6.07BMarket Cap
Guizhou Bailing Group Pharmaceutical Co., Ltd. Class A
SZSE:002424
(Shenzhen Stock Exchange)

Recent

price

4.60

P/E

ratio

- -

div

yld

0.97%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.69
0.8
0.97
0.99
1.12
1.34
1.56
1.82
2.23
2.02
2.23
2.1
2.56
3.09
2.28
2.34
1.9
Revenue per Share
0.13
0.15
0.16
0.19
0.22
0.29
0.34
0.37
0.4
0.2
0.11
0.08
0.1
-0.3
0.02
-0.08
-0.08
Basic EPS, GAAP
-0.49
0.01
-0.11
0.04
0.21
0.21
0.22
-0.03
-0.2
0.24
0.33
-0.07
0.31
0.02
-0.02
0.48
- -
Free Cash Flow per Basic Share
0.07
0.13
0.11
0.17
0.1
0.1
0.1
0.1
0.11
0.15
0.31
0.07
0.06
0.06
0.05
0.05
0.04
Dividend per Share
1.31
1.36
1.43
1.49
1.65
1.88
2.14
2.42
2.75
2.87
2.76
2.75
2.83
2.32
2.28
2.26
2.28
Book Value per Share
1.29
1.22
1.3
1.35
1.48
1.72
1.96
2.22
2.54
2.63
2.57
2.49
2.58
2.05
1.97
1.94
1.96
Tangible Book Value per Share
1,249
1,421
1,415
1,419
1,411
1,419
1,419
1,422
1,408
1,414
1,385
1,481
1,385
1,382
1,681
1,305
1,376
Basic Weighted Avg Shares
864
1,138
1,368
1,405
1,575
1,899
2,214
2,592
3,137
2,851
3,088
3,111
3,540
4,263
3,825
3,049
2,619
Sales/Revenue/Turnover
23.27
24.97
20.87
25.93
26.07
27.91
27.41
25.48
22.91
17.89
10.87
9.82
9.14
-6.15
3.22
7.45
7.92
Operating Margin (%)
14
28
45
48
64
71
75
73
80
89
96
107
116
117
117
124
- -
Depreciation Expense
158
208
222
270
310
411
482
526
563
283
152
118
138
-415
34
-104
-103
Net Income, GAAP
16.54
13.22
13.11
16.3
16.45
15.4
16.15
15.85
14.13
20.01
26.37
22.66
14.34
- -
45.05
354.8
348.29
Effective Tax Rate (%)
18.32
18.3
16.21
19.18
19.72
21.66
21.78
20.3
17.96
9.92
4.93
3.81
3.91
-9.72
0.88
-3.42
-3.95
Profit Margin (%)
1,778
1,623
1,289
1,264
1,460
1,784
2,081
2,325
1,974
1,914
1,720
1,081
1,051
209
-156
-76
-63
Working Capital
130
200
70
- -
- -
- -
- -
- -
- -
213
269
58
47
239
71
153
11
LT Debt
1,847
1,940
2,043
2,127
2,348
2,681
3,065
3,467
3,937
4,136
3,920
3,877
3,996
3,282
3,199
3,175
3,200
Total Equity
9.32
7.76
7.74
8.76
9.78
11.94
13.07
12.93
11.6
4.79
2.31
2.35
2.49
- -
0.05
-4.42
-4.32
Return on Invested Capital (%)
11.26
10.16
9.97
10.07
11.08
13.22
13.61
12.72
12.11
6.12
3.86
3.62
4.07
- -
1.55
-2.45
- -
Return on Capital (%)
14.24
11.08
11.26
13.06
14.02
16.56
17.02
16.34
15.43
7.13
3.84
3.05
3.52
-11.42
1.04
-3.29
-3.24
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,077
1,119
1,051
LT Borrowings
139
- -
- -
LT Finance Leases
14
13
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,398
1,398
1,398
Market Capitalization
6,080
7,240
6,066

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,724
2,526
2,348
Cash, Cash Equivalents & STI
355
181
181
Accounts Receivable, Net
1,287
1,445
1,210
Inventories
666
658
706
Total Current Liabilities
2,800
2,669
2,412
Payables & Accruals
- -
- -
- -
ST Debt
1,077
1,119
1,051
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.17%
-3.84%
-0.76%
Free Cash Flow
-264.58%
-597.87%
-1,989.49%
Net Income, GAAP
-98.58%
-184.65%
-410.41%
Sales/Revenue/Turnover
5.83%
0.88%
-20.31%
Total Cash Common Dividend
3.19%
-23.91%
-23.2%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,333
810
633
1,050
3,825
2025
761
701
- -
947
3,049
2026
644
326
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.03
- -
-0.04
0.02
2025
0.02
0.02
- -
-0.12
-0.08
2026
0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.02
0.01
0.01
0.05
2025
0.01
0.01
- -
0.01
0.05
2026
0.01
0.01
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Guizhou Bailing Group Pharmaceutical Co., Ltd. Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) engages in the research, development, production, and sales of Miao ethnic medicines and traditional Chinese medicines in China. The company manufactures and distributes a broad portfolio of pharmaceutical products in various forms, including tablets, capsules, granules, syrups, powders, pills, tinctures, sprays, lotions, and creams; key offerings encompass Yindan XinnaoTong softgels for cardiovascular and cerebrovascular conditions, Vitamin C Yinqiao tablets and cough relief syrups and capsules for respiratory ailments, pediatric Chai Gui antipyretic granules, Jin Gan capsules, Shuangyang Pharyngology capsules, Kang Fuling capsules, Compound Yizhi Huanghua spray, Jingdanning capsules, cough relief granules, Sugar Ning Tongluo capsules and tablets, Bailing Capsules, Jiangsu Bailing Jiedu Capsule, and Sevibacillin, primarily targeting treatments for cardiovascular and cerebrovascular diseases, cough and cold, pediatric fever, gynecologic conditions, and related therapeutic areas. Founded in 1999 and headquartered in Anshun, Guizhou Province, China, the company operates extensive production facilities with capacities exceeding 5 billion tablets and 3 billion capsules annually, maintains a distribution network across over 30 provinces domestically, and exports to more than 20-30 countries including Southeast Asia and Europe, contributing around 10-15% of revenue from international markets; it employs approximately 6,000-6,500 personnel and emphasizes sustainability through reduced water usage and waste generation. In recent developments, Guizhou Bailing Group Pharmaceutical Co., Ltd. has advanced direct sales reforms across 15 provinces since a 2022 pilot in nine regions to boost sales efficiency and profitability, announced a 1 billion CNY research and development investment plan over three years in 2023 to enhance innovative drug formulations, acquired a local biotech firm for 500 million CNY in 2023 to strengthen its pipeline, formed a strategic partnership with a leading research university in 2023 for new therapeutic solutions projected to generate 200 million CNY annual revenue from 2024, authorized a share buyback plan in February 2024, and continues pipeline advancements including Huang Lian Jie Du Pill, Yishen Huazhuo Granules, Bing Liancao Lozenges, and Shaoling Tablets while pursuing high-quality growth amid improved cost controls and market share of about 1.5% in traditional Chinese medicine.